Strides Pharma Science: Unanticipated De-Growth Across Markets..
Strides reported a weak quarter witnessing a de-growth across revenues of 12% YoY to Rs.688cr during Q1FY22 owing to major sector headwinds such as...
191 Views
India Small Caps: Position for Outperformance Vs Large & Mid Caps
Late Friday evening, the Securities and Exchange Board of IndianÂ
694 Views
Screening the Silkroad: Small-Mid Cap High-Risk Names to Avoid: Q2 2019
The risk remains apparent - but list reduced in number over Q2 Q1-2019 Small-Mid Cap High-Risk list of stocks ( Screening the Silkroad: Small-Mid...
592 Views
Screening the Silkroad: Small-Mid Cap - Possible High-Risk Names: Q1 2019
Increasing risk apparent Q4-2018 Small-Mid Cap High-Risk screen ( Screening the Silkroad:Â Small-Mid Cap -Â High-Risk Names To Avoid Q4 2018 )...
663 Views
Eris Lifesciences Ltd - Q4FY18 Beats Expectations, FY19E on Track
Eris Lifesciences Limited (ERIS IN) reported Q4FY18 results recently. Performance Highlights Eris reported Q4FY18 consolidated revenues at Rs 2.1...
175 Views